The Japanese venture CanBas is pressing ahead with plans for a Phase III clinical trial for its lead development project CBP501 in non-small cell lung cancer (NSCLC), despite mixed preliminary efficacy results in a Phase II study in this setting.
The Japanese venture CanBas is pressing ahead with plans for a Phase III clinical trial for its lead development project CBP501 in non-small cell lung cancer (NSCLC), despite mixed preliminary efficacy results in a Phase II study in this setting.
The US-based program is comparing the dodecapeptide therapy in combination with cisplatin and pemetrexed with these two standard-of-care drugs alone as a first-line treatment for locally advanced or metastatic non-squamous...
The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.
The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.
Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.
